Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...